Welcome to our dedicated page for Syra Health SEC filings (Ticker: SYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Syra Health Corp.’s (SYRA) SEC filings, offering detailed insight into the company’s healthcare technology and solutions business. Through its periodic reports and current reports, Syra Health discloses information about its population health, behavioral and mental health, and healthcare workforce activities, as well as its capital structure and corporate governance.
Annual reports on Form 10-K and quarterly reports on Form 10-Q typically include discussions of Syra Health’s business units, risk factors, and financial statements. These filings describe revenue contributions from areas such as Population Health and Healthcare Workforce, cost structures, and the company’s use of non-GAAP measures like adjusted EBITDA to analyze operating performance and liquidity.
Current reports on Form 8-K provide updates on material events. For Syra Health, recent 8-K filings have addressed topics such as leadership changes, including the appointment of a new Chief Executive Officer, amendments to the Amended and Restated Certificate of Incorporation affecting Class B common stock, and the release of quarterly financial results via press release. An 8-K has also described the company’s voluntary delisting from the Nasdaq Capital Market and related expectations regarding OTC trading.
Proxy statements on Schedule 14A contain information about Syra Health’s annual meeting of stockholders, Board composition, voting rights for Class A and Class B common stock, and proposals such as amendments to the certificate of incorporation and auditor ratification. These documents help investors understand the company’s governance framework and stockholder voting structure.
On Stock Titan, Syra Health’s SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries highlight key points from long documents, helping readers quickly identify items such as segment performance, contract disclosures, governance changes, and capital market actions. Users can review Forms 10-K and 10-Q for comprehensive financial details, 8-K filings for significant events, and proxy materials for governance information, while also tracking any insider-related filings such as Form 4 if and when they are available.
Syra Health Corp. filed Amendment No. 1 to its annual report to add detailed Part III information on directors, executive compensation, ownership and auditor fees, without changing previously issued financial statements. The filing confirms Gregory R. Alexander as Chief Executive Officer effective January 5, 2026 with a base salary of $251,000, equity awards and change‑of‑control protections. It outlines compensation for former leaders, including the prior CEO and president, and notes no bonuses were paid for 2025. The amendment describes board and committee cash retainers, substantial option grants to non‑employee directors, and the 2022 Omnibus Equity Incentive Plan with 1,041,667 shares reserved. It also discloses related‑party service and lease arrangements, major shareholders’ voting power, and audit and audit‑related fees paid to M&K for 2025 and 2024.
Syra Health Corp. filed its annual report describing a small but loss-making healthcare solutions business focused on mental health, population health, digital health, education, and staffing. The company generated approximately $7.2 million of revenue in 2025, down from $8.0 million in 2024, and reported net losses of $896,333 and $3,759,238 for those years. Cash was $1,614,733 as of December 31, 2025, and its auditors expressed substantial doubt about its ability to continue as a going concern, highlighting the need for substantial additional funding. Syra operates in heavily regulated healthcare and government-contract markets and outlines numerous operational, regulatory, technology, data security, concentration, and staffing risks that could materially affect its business. Non-affiliate equity market value was about $979,537 as of June 30, 2025, with 11,339,169 Class A shares outstanding as of March 12, 2026.
Syra Health Corp. reported FY2025 results showing a much smaller loss and stronger margins despite lower revenue. Net revenues were $7.2 million versus $8.0 million in FY2024, mainly due to reduced federal funding to state and county customers.
Population Health revenue grew 157% to $5.3 million, becoming a key growth engine. Net loss narrowed to ($896,333) from ($3,759,238), and earnings per share improved to ($0.08) from ($0.50). Gross margin increased to 34.4% from 20.7% as cost of services fell.
Total operating expenses declined to $3.4 million from $5.4 million, and adjusted EBITDA improved to ($863K) from ($3.7 million). Cash was $1.6 million with no long-term debt as of December 31, 2025, while management highlighted a strategic shift toward integrated healthcare solutions and reiterated a goal of reaching profitability by year-end 2026.
Syra Health Corp. reported that CEO Gregory R. Alexander received new equity awards. On January 5, 2026, he was granted 110,537 restricted stock units at $0.00 per unit and 257,920 stock options with a $0.09 exercise price.
For both grants, 20% vest one year after the grant date. The remaining 80% vest in equal installments over the following four years on each anniversary of the grant date, aligning his compensation with longer-term company performance.
Syra Health Corp shareholder Neil Johnson filed a Schedule 13D reporting beneficial ownership of 700,312 shares of Class A common stock, representing 6.2% of the company. Johnson, an individual based in Ohio who works in consulting, acquired the position using personal funds. The filing notes that his purpose of transaction is "Influence," indicating he may seek to play an active role in matters affecting the company.
The disclosure also shows that on January 13, 2026, Johnson was involved in a transaction for 38,182 shares at a price of $0.085 per share. He reports sole voting power over 700,312 shares, with no shared voting or dispositive power, and no disclosed contracts or arrangements related to these securities.
Syra Health Corp's chief executive officer reports no beneficial ownership of company securities. A Form 3 initial statement of beneficial ownership was filed for Gregory R. Alexander, who is identified as the Chief Executive Officer of Syra Health Corp (ticker SYRA). The filing shows no non-derivative or derivative securities listed in the ownership tables, and the explanation section states that no securities are beneficially owned. This means the CEO is not reporting ownership of Syra Health stock or related derivative instruments as of the event date in this filing.
Syra Health Corp director Radhika Mereddy filed an initial insider ownership report on Form 3. This filing states that, as of the event date of 08/13/2025, she had no securities beneficially owned in Syra Health Corp. Both the non-derivative and derivative securities tables show no holdings, and the explanation of responses confirms that no securities are beneficially owned.
Syra Health Corp. appointed Gregory R. Alexander as Chief Executive Officer under an employment agreement effective January 5, 2026.
The agreement provides a $251,000 annual base salary, a target bonus equal to 30% of base pay, 110,537 restricted stock units, options to purchase 257,920 shares of Class B common stock and 368,458 performance stock units, with specified vesting dates and performance conditions. It also includes non-competition and non-solicitation covenants, cash severance of six months’ base salary plus bonus and benefits in certain terminations without cause or for good reason, and accelerated vesting of unvested equity if his employment ends in connection with defined change of control scenarios.
Syra Health Corp (SYRA) reported a new stock option grant to director Vijayapal R. Reddy. On 11/21/2025, he received stock options with an exercise price of $0.07 per share for 43,348 shares of Class A common stock, expiring on 11/21/2035.
The options were issued under the company’s 2022 Omnibus Equity Incentive Plan. One-third of the options vest on December 31, 2025, with the remaining two-thirds vesting in equal portions on December 31, 2026 and December 31, 2027. After this grant, Reddy beneficially owns 70,926 derivative securities (stock options).
Syra Health Corp (SYRA) reported a new equity award to one of its directors. On 11/21/2025, the director received stock options to acquire 43,348 shares of Class A common stock at an exercise price of $0.07 per share under the company’s 2022 Omnibus Equity Incentive Plan.
One-third of these options vest on December 31, 2025, with the remaining two-thirds vesting in equal portions on December 31, 2026 and December 31, 2027. Following this grant, the director beneficially owns 77,821 derivative securities directly, aligning compensation with the company’s future share performance.